|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net income | |||||
| Less: Income from discontinued operations, net of tax | |||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||
| Depreciation, amortization and impairments | |||||
| Contingent acquisition considerations fair value adjustments | |||||
| Change in deferred income taxes | |||||
| Stock-based compensation | |||||
| Non-cash interest expense | |||||
| Provision for bad debts and inventory charges | |||||
| Loss on debt financing transactions | |||||
| Gain on remeasurement of debt and other | |||||
| Foreign currency transaction net losses, (gain) on sale of assets and other, net | |||||
| Changes in assets and liabilities, net of effects of acquisitions: | |||||
| Receivables | |||||
| Inventories | |||||
| Other assets and liabilities | |||||
| Income taxes payable, net | |||||
| Accounts payable and accrued liabilities | |||||
| Net cash provided by (used in) operating activities from continuing operations | |||||
| Net cash provided by operating activities from discontinued operations | |||||
| Net cash provided by operating activities | |||||
| Cash flows from investing activities: | |||||
| Capital expenditures | |||||
| Acquisitions of businesses and assets, net of cash acquired | |||||
| Proceeds from settlement of cross-currency interest rate swaps | |||||
| Proceeds from sale of investments and other, net(1) | |||||
| Net cash used in investing activities from continuing operations | |||||
| Net cash (used in) provided by investing activities from discontinued operations(1) | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities: | |||||
| Borrowings under revolving credit facilities | |||||
| Repayments under revolving credit facilities | |||||
| Proceeds from issuance of senior notes and term loans | |||||
| Repayments of notes and term loans (including redemption premium) | |||||
| Payments on long-term debt | |||||
| Payments of debt issuance and deferred financing costs | |||||
| Payments on license obligations | |||||
| Payments of contingent acquisition considerations | |||||
| Purchase of L&W common stock | |||||
| Purchase of SciPlay’s Class A common stock and acquisition of noncontrolling interest | |||||
| Acquisition of SciPlay noncontrolling interest | |||||
| Net redemptions of common stock under stock-based compensation plans and other | |||||
| Net cash used in financing activities from continuing operations | |||||
| Net cash used in financing activities from discontinued operations | |||||
| Net cash used in financing activities | |||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | |||||
| Decrease in cash, cash equivalents and restricted cash | |||||
| Cash, cash equivalents and restricted cash, beginning of period | |||||
| Cash, cash equivalents and restricted cash, end of period | |||||
| Less: Cash, cash equivalents and restricted cash of discontinued operations | |||||
| Cash, cash equivalents and restricted cash of continuing operations, end of period | |||||
| Cash paid for interest | |||||
| Income taxes paid | |||||
| Distributed earnings from equity investments | |||||
| Cash paid for contingent acquisition considerations included in operating activities | |||||
Loading...